OBS Medical is pleased to announce its formation from the successful merger of Oxford BioSignals Ltd and t+ Medical Ltd.
The previously separate but co-located companies, each with its origins in Oxford University, have come together in a long anticipated merger. The convergence of technology and developments in the healthcare and pharmaceutical sectors makes the merger of the two businesses a natural and highly complementary change.
OBS Medical will now expand its unique range of real-time monitoring products for secondary care (vital signs), primary care (long term conditions) and pharmaceutical trials and drug development. The company is in an exciting field where its innovative products are able to address its customers’ demands for improved health outcomes and lower costs.
With its head office at Abingdon, Oxfordshire and US operations in Indianapolis and North Carolina the company is able to work with the world’s leading authorities and companies in their respective fields to bring its proven evidence based innovation to its customers.
The new company will continue the previous two companies’ propensity to collaborate with partners around the world who share the same vision and passion for excellence.
For further information contact:
Or email: info@obsmedical.com